125 related articles for article (PubMed ID: 38009308)
41. RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypes.
Pesch AM; Hirsh NH; Michmerhuizen AR; Jungles KM; Wilder-Romans K; Chandler BC; Liu M; Lerner LM; Nino CA; Ward C; Cobain EF; Lawrence TS; Pierce LJ; Rae JM; Speers CW
JCI Insight; 2022 Feb; 7(3):. PubMed ID: 34932500
[TBL] [Abstract][Full Text] [Related]
42. Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer.
Ye L; Li F; Song Y; Yu D; Xiong Z; Li Y; Shi T; Yuan Z; Lin C; Wu X; Ren L; Li X; Song L
Int J Cancer; 2018 Nov; 143(10):2602-2613. PubMed ID: 30151890
[TBL] [Abstract][Full Text] [Related]
43. Long non-coding RNA MALAT1 promotes proliferation and invasion via targeting miR-129-5p in triple-negative breast cancer.
Zuo Y; Li Y; Zhou Z; Ma M; Fu K
Biomed Pharmacother; 2017 Nov; 95():922-928. PubMed ID: 28915533
[TBL] [Abstract][Full Text] [Related]
44. Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer.
Zhang Y; Lv L; Zheng R; Xie R; Yu Y; Liao H; Chen J; Zhang B
Breast Cancer Res; 2023 Jun; 25(1):75. PubMed ID: 37365643
[TBL] [Abstract][Full Text] [Related]
45. The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer.
Thies KA; Cole MW; Schafer RE; Spehar JM; Richardson DS; Steck SA; Das M; Lian AW; Ray A; Shakya R; Knoblaugh SE; Timmers CD; Ostrowski MC; Chakravarti A; Sizemore GM; Sizemore ST
Breast Cancer Res; 2021 Jun; 23(1):65. PubMed ID: 34118960
[TBL] [Abstract][Full Text] [Related]
46. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
[TBL] [Abstract][Full Text] [Related]
47. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
[TBL] [Abstract][Full Text] [Related]
48. CircDUSP1 regulates tumor growth, metastasis, and paclitaxel sensitivity in triple-negative breast cancer by targeting miR-761/DACT2 signaling axis.
Huang S; Xie J; Lei S; Fan P; Zhang C; Huang Z
Mol Carcinog; 2023 Apr; 62(4):450-463. PubMed ID: 36562476
[TBL] [Abstract][Full Text] [Related]
49. STAT1 Mediates the Transcription of CircIFI30 and Promotes the Progression of Triple-Negative Breast Cancer by Up-Regulating CDCA4.
Zhang J; Xia S; Liu X; Qi D; He X; Chen D
J Environ Pathol Toxicol Oncol; 2022; 41(1):1-13. PubMed ID: 35378000
[TBL] [Abstract][Full Text] [Related]
50. CIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer.
Black JL; Harrell JC; Leisner TM; Fellmeth MJ; George SD; Reinhold D; Baker NM; Jones CD; Der CJ; Perou CM; Parise LV
Breast Cancer Res Treat; 2015 Jul; 152(2):337-46. PubMed ID: 26105795
[TBL] [Abstract][Full Text] [Related]
51. Circular RNA circ-ERBB2 Elevates the Warburg Effect and Facilitates Triple-Negative Breast Cancer Growth by the MicroRNA 136-5p/Pyruvate Dehydrogenase Kinase 4 Axis.
Huang Y; Zheng S; Lin Y; Ke L
Mol Cell Biol; 2021 Sep; 41(10):e0060920. PubMed ID: 34370552
[TBL] [Abstract][Full Text] [Related]
52. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE
Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567
[TBL] [Abstract][Full Text] [Related]
53. Resveratrol exhibits diverse anti-cancer activities through epigenetic regulation of E-cadherin and p21 in triple-negative breast cancer cells.
Sakamoto T; Tanimoto K; Eguchi H; Sasaki S; Tsuboi K; Hayashi SI; Ichihara S
Breast Cancer; 2023 Sep; 30(5):727-738. PubMed ID: 37166625
[TBL] [Abstract][Full Text] [Related]
54. The chromatin architectural regulator SND1 mediates metastasis in triple-negative breast cancer by promoting CDH1 gene methylation.
Zhang H; Gao M; Zhao W; Yu L
Breast Cancer Res; 2023 Oct; 25(1):129. PubMed ID: 37885030
[TBL] [Abstract][Full Text] [Related]
55. CTCF-Induced lncRNA C5orf66-AS1 Facilitates the Progression of Triple-Negative Breast Cancer via Sponging miR-149-5p to Up-Regulate CTCF and CTNNB1 to Activate Wnt/β-Catenin Pathway.
Zhu S; Sun J; Liu X; Shao H; Feng C; Wang Z; Zheng X; Wei S
Mol Cell Biol; 2022 Jun; 42(6):e0018821. PubMed ID: 35499320
[TBL] [Abstract][Full Text] [Related]
56. STAT3-induced HLA-F-AS1 promotes cell proliferation and stemness characteristics in triple negative breast cancer cells by upregulating TRABD.
Wu D; Jia H; Zhang Z; Li S
Bioorg Chem; 2021 Apr; 109():104722. PubMed ID: 33618253
[TBL] [Abstract][Full Text] [Related]
57. MiR-6838-5p suppresses cell metastasis and the EMT process in triple-negative breast cancer by targeting WNT3A to inhibit the Wnt pathway.
Liu G; Wang P; Zhang H
J Gene Med; 2019 Dec; 21(12):e3129. PubMed ID: 31693779
[TBL] [Abstract][Full Text] [Related]
58. CircWAC induces chemotherapeutic resistance in triple-negative breast cancer by targeting miR-142, upregulating WWP1 and activating the PI3K/AKT pathway.
Wang L; Zhou Y; Jiang L; Lu L; Dai T; Li A; Chen Y; Zhang L
Mol Cancer; 2021 Mar; 20(1):43. PubMed ID: 33648498
[TBL] [Abstract][Full Text] [Related]
59. Long non-coding RNA HUMT hypomethylation promotes lymphangiogenesis and metastasis via activating FOXK1 transcription in triple-negative breast cancer.
Zheng S; Yang L; Zou Y; Liang JY; Liu P; Gao G; Yang A; Tang H; Xie X
J Hematol Oncol; 2020 Mar; 13(1):17. PubMed ID: 32138762
[TBL] [Abstract][Full Text] [Related]
60. MicroRNA-1246 suppresses the metastasis of breast cancer cells by targeting the DYRK1A/PGRN axis to prevent the epithelial-mesenchymal transition.
Wang P; Chen W; Zhang Y; Zhong Q; Li Z; Wang Y
Mol Biol Rep; 2022 Apr; 49(4):2711-2721. PubMed ID: 35059968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
